Lightcalls.com
 

A Harvard University consideration...

A Harvard University consideration concludes that one in five just discovered prescription drugs may ultimately be recalled or will bring out harmful side effects.

Researchers in Cambridge, Massachusetts evaluated 548 remedys that were initially marketed between 1975 and 1999 They anticipateed up drug recalls and scanned the Physician's Desk respect a commonly used source of information, for warnings in succession side effects.

During that time, 10 percent of strange drugs either received warnings or were withdrawn--half within seven years after they first appeared in succession the market. Based on these ends the team calculates that each just discovered drug has a 20 percent chance--over a 25-year period--of being withdrawn or producing unexpect side effects

The consideration found that 56 of 548 modern drugs approved by the US meat and Drug Administration (FDA) during the 25-year period were banned from the market altogether or enthralled to so-called "black box" safety warnings--notations situationed on drug labels to inform physicians of potentially dangerous side general intents or interactions.

Side events from new drugs can have widespread impact. Almost 20 million Americans took individual or more of the five medicines that were withdrawn in the year between September 1997 and September 1998 In a cases, those side effects can be deadly: Since 1993 seven put drugs intos that were approved, then later withdrawn, may have contributed to from one side of to the other 1,000 deaths.



Several high-profile unsalable articles have been pulled from the market on regulators over the past not many years. One drug, the antihistamine terfenadine--marketed below the name Seldane--spent nearly 13 years forward the market before being banned in 1998 Another, the gastrointestinal physic cisapride, was available for throughout six years. Both drugs were haped because researchers discovered high rates of heart toxicity associated with their use. The investigation appears in the May 1 2002 issue of the Journal of the American Medical Association.

COPYRIGHT 2002 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2002 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.